| Long name: |
FITC Conjugated, AVPR1B/AVP Receptor V3 Antibody |
| Category: |
Conjugated Primary Antibodies |
| Conjugation: |
Anti-FITC Antibody |
| Host Organism: |
Rabbit (Oryctolagus cuniculus) |
| Target Antigen: |
AVPR1B/AVP Receptor V3 |
| Specificity: |
This is a highly specific antibody against AVPR1B/AVP Receptor V3 |
| Modification: |
Unmodified |
| Modification site: |
None |
| Clonality: |
Polyclonal |
| Clone: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Subcellular location: |
Extracellular |
| Source: |
KLH conjugated synthetic peptide derived from human AVP Receptor V3 |
| Tested applications: |
IF(IHC-P), FCM |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), FCM(1:20-100) |
| Crossreactivity: |
Mouse, Rat, Human |
| Crossreactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Antigen background: |
AVP mediates its effects through a family of G-protein coupled receptors, AVP receptor antagonists may have potential therapeutic effects in hypertension, It is detected as a full length protein and a shorter protein, Mutations in the V2 receptor result in nephrogenic diabetes insipidus (NDI), The AVP Receptor V2 activates the Gs protein and the cyclic AMP second messenger system (7), The AVP receptor V1a is responsible for several functions, The AVP receptor V3 is preferentially expressed in the pituitary and stimulates the release of adrenocorticotropic hormone (ACTH) in response to AVP by mobilizing intracellular calcium stores (8), The V1a receptor is coupled to Gq/11 protein, The human AVP receptor V2 gene maps to chromosome Xq28 and is expressed in lung and kidney (5, V2 and V3 (also designated V1b) (1, a rare X-linked disorder characterized by the inability of the kidney to concentrate urine in response to AVP (5, congestive heart failure, including blood vessel constriction, is a cyclic nonpeptide that is involved in the regulation of body fluid osmolality (1-3), liver glycogenolysis and platelet adhesion (3), nephrotic syndrome and ACTH-secreting tumors (2), the antidiuretic hormone, the vasopressin receptors type V1a, which increases the intracellular calcium concentration (3), which results from proteolytic cleavage of its amino terminus (4), 2), 6), 7), Vasopressin (AVP) |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA |
| Excitation Emission: |
494nm/518nm |
| Properties: |
Bioss Primary Conjugated Antibodies FITC is highly sensitive to pH extremes, FITC has a green emission that's usually collected at 530 nanometers, FITC has a high quantum yield (efficiency of energy transfer from absorption to emission fluorescence) and approximately half of the absorbed photons are emitted as fluorescent light, For fluorescent microscopy applications, This Bioss Primary Conjugated Antibodies Fluorescein isothiocyanate (FITC) antibody is currently after some BD antibodies the most commonly used fluorescent dye for FACS, When excited at 488 nanometers, its photo bleaching effects are not observed due to a very brief interaction at the laser intercept, the 1 FITC is seldom used as it photo bleaches rather quickly though in flow cytometry applications, the FL1 detector of a FACSCalibur or FACScan, C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
AVPR1B/AVP Receptor V3 Conjugated |
| Short name: |
FITC Conjugated, AVPR1B/AVP Receptor V3 Antibody |
| Technique: |
Fluorescein, antibodies against human proteins, antibodies for, antibody Conjugates, Antibody |
| Label: |
FITC |
| Alternative name: |
fluorecein coupled, arginine vasopressin receptor 1B/arginine vasopressin Receptor V3 (Antibody to) |
| Alternative technique: |
antibodies |
| Alternative to gene target: |
ADH and ARVP and AVP-NPII and AVRP and VP, AVP and IDBG-45432 and ENSG00000101200 and 551, AVP and IDBG-640134 and ENSBTAG00000008027 and 280728, AVPR1B and IDBG-106206 and ENSG00000198049 and 553, AVPR1B and IDBG-628969 and ENSBTAG00000017301 and 282861, AVPR3, Avp and IDBG-206576 and ENSMUSG00000037727 and 11998, Avpr1b and IDBG-191336 and ENSMUSG00000026432 and 26361, Extracellular, Plasma membranes, arginine vasopressin receptor 1B, cysteine-type endopeptidase inhibitor activity involved in apoptotic process, protein kinase C binding, this GO :0001992 and regulation of systemic arterial blood pressure by vasopressin and biological process this GO :0004930 and G-protein coupled receptor activity and molecular function this GO :0005000 and vasopressin receptor activity and molecular function this GO :0005080 and protein kinase C binding and molecular function this GO :0005768 and endosome and cellular component this GO :0005886 and plasma membrane and cellular component this GO :0005887 and integral component of plasma membrane and cellular component this GO :0007186 and G-protein coupled receptor signaling pathway and biological process this GO :0007202 and activation of phospholipase C activity and biological process this GO :0007204 and positive regulation of cytosolic calcium ion concentration and biological process this GO :0016021 and integral component of membrane and cellular component, this GO :0002125 and maternal aggressive behavior and biological process this GO :0003084 and positive regulation of systemic arterial blood pressure and biological process this GO :0004672 and protein kinase activity and molecular function this GO :0004871 and signal transducer activity and molecular function this GO :0005102 and receptor binding and molecular function this GO :0005184 and neuropeptide hormone activity and molecular function this GO :0005185 and neurohypophyseal hormone activity and molecular function this GO :0005515 and protein binding and molecular function this GO :0005576 and extracellular region and cellular component this GO :0005615 and extracellular space and cellular component this GO :0005829 and cytosol and cellular component this GO :0006091 and generation of precursor metabolites and energy and biological process this GO :0006468 and protein phosphorylation and biological process this GO :0006833 and water transport and biological process this GO :0007165 and signal transduction and biological process this GO :0007204 and positive regulation of cytosolic calcium ion concentration and biological process this GO :0007267 and cell-cell signaling and biological process this GO :0007621 and negative regulation of female receptivity and biological process this GO :0007625 and grooming behavior and biological process this GO :0007626 and locomotory behavior and biological process this GO :0008284 and positive regulation of cell proliferation and biological process this GO :0010628 and positive regulation of gene expression and biological process this GO :0014049 and positive regulation of glutamate secretion and biological process this GO :0014070 and response to organic cyclic compound and biological process this GO :0030141 and secretory granule and cellular component this GO :0030307 and positive regulation of cell growth and biological process this GO :0030425 and dendrite and cellular component this GO :0030819 and positive regulation of cAMP biosynthetic process and biological process this GO :0031394 and positive regulation of prostaglandin biosynthetic process and biological process this GO :0031894 and V1A vasopressin receptor binding and molecular function this GO :0031895 and V1B vasopressin receptor binding and molecular function this GO :0032849 and positive regulation of cellular pH reduction and biological process this GO :0033138 and positive regulation of peptidyl-serine phosphorylation and biological process this GO :0033574 and response to testosterone and biological process this GO :0035094 and response to nicotine and biological process this GO :0035176 and social behavior and biological process this GO :0035813 and regulation of renal sodium excretion and biological process this GO :0042310 and vasoconstriction and biological process this GO :0042538 and hyperosmotic salinity response and biological process this GO :0042711 and maternal behavior and biological process this GO :0043027 and cysteine-type endopeptidase inhibitor activity involved in apoptotic process and molecular function this GO :0043066 and negative regulation of apoptotic process and biological process this GO :0043084 and penile erection and biological process this GO :0043154 and negative regulation of cysteine-type endopeptidase activity involved in apoptotic process and biological process this GO :0043252 and sodium-independent organic anion transport and biological process this GO :0045087 and innate immune response and biological process this GO :0045471 and response to ethanol and biological process this GO :0045907 and positive regulation of vasoconstriction and biological process this GO :0050891 and multicellular organismal water homeostasis and biological process this GO :0051970 and negative regulation of transmission of nerve impulse and biological process this GO :0055085 and transmembrane transport and biological process this GO :0070371 and ERK1 and ERK2 cascade and biological process this GO :0070528 and protein kinase C signaling and biological process this GO :0090201 and negative regulation of release of cytochrome c from mitochondria and biological process, this GO :0004672 : protein kinase activity, this GO :0004672 : protein kinase activity and also this GO :0004871 : signal transducer activity and also this GO :0005102 : receptor binding and also this GO :0005184 : neuropeptide hormone activity and also this GO :0005185 : neurohypophyseal hormone activity and also this GO :0005515 : protein binding and also this GO :0031894 : V1A vasopressin receptor binding and also this GO :0031895 : V1B vasopressin receptor binding and also this GO :0043027 : cysteine-type endopeptidase inhibitor activity involved in apoptotic process, this GO :0004871 : signal transducer activity, this GO :0004930 : G-protein coupled receptor activity, this GO :0004930 : G-protein coupled receptor activity and also this GO :0005000 : vasopressin receptor activity and also this GO :0005080 : protein kinase C binding, this GO :0005000 : vasopressin receptor activity, this GO :0005080 : protein kinase C binding, this GO :0005102 : receptor binding, this GO :0005184 : neuropeptide hormone activity, this GO :0005185 : neurohypophyseal hormone activity, this GO :0005515 : protein binding, this GO :0031894 : V1A vasopressin receptor binding, this GO :0031895 : V1B vasopressin receptor binding, this GO :0043027 : cysteine-type endopeptidase inhibitor activity involved in apoptotic process, arginine vasopressin |
| Identity: |
896 |
| Gene: |
AVPR1B |
More about : AVPR1B |
| Long gene name: |
arginine vasopressin receptor 1B |
| Synonyms gene: |
AVPR3 |
| Locus: |
1q32, 1 |
| Discovery year: |
1995-07-06 |
| GenBank acession: |
D31833 |
| Entrez gene record: |
553 |
| Pubmed identfication: |
7929452 8586456 |
| RefSeq identity: |
NM_000707 |
| Classification: |
Arginine vasopressin and oxytocin receptors |
| Havana BLAST/BLAT: |
OTTHUMG00000184377 |